Cancers Associated With Mesothelin Expression clinical trials at UC Cancer
1 research study open to eligible people
Showing trials for
Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression
open to eligible people ages 18 years and up
An open-label, Phase 1/2a study of HPN536 as monotherapy to assess the safety, tolerability and PK in patients with advanced cancers associated with mesothelin expression.
at UCLA
Last updated: